Kalaris published a press release reporting full-year financial results and business updates. For FY 2025, net loss was USD 43.44 million, narrowing 37.2%, while research and development expenses fell 31.7% to USD 30.75 million, mainly due to a USD 32.0 million royalty obligation expense recorded in the prior year. General and administrative expenses rose more than doubled to USD 15.4 million, driven by higher insurance, legal, accounting and other professional fees and personnel costs related to operating as a public company. Cash, cash equivalents and marketable securities totaled USD 117.98 million at year-end, and Kalaris said this is expected to fund operations into the fourth quarter of 2027. On the pipeline, Kalaris reported positive initial Phase 1a single-ascending-dose data for TH103 in treatment-naïve nAMD patients, said preliminary Phase 1b/2 data are expected in the first half of 2027, and plans to initiate Phase 3 trials by year-end 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603170800PRIMZONEFULLFEED9673076) on March 17, 2026, and is solely responsible for the information contained therein.